IL264664A - - Google Patents
Info
- Publication number
- IL264664A IL264664A IL26466419A IL26466419A IL264664A IL 264664 A IL264664 A IL 264664A IL 26466419 A IL26466419 A IL 26466419A IL 26466419 A IL26466419 A IL 26466419A IL 264664 A IL264664 A IL 264664A
- Authority
- IL
- Israel
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377154P | 2016-08-19 | 2016-08-19 | |
| PCT/IB2017/001140 WO2018033792A2 (en) | 2016-08-19 | 2017-08-18 | Ophthalmic pharmaceutical compositions and uses relating thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL264664A true IL264664A (https=) | 2019-03-31 |
| IL264664B IL264664B (en) | 2022-11-01 |
| IL264664B2 IL264664B2 (en) | 2023-03-01 |
Family
ID=60935566
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264664A IL264664B2 (en) | 2016-08-19 | 2017-08-18 | Ophthalmic pharmaceutical preparations and uses related to them |
| IL297367A IL297367A (en) | 2016-08-19 | 2017-08-18 | Ophthalmic pharmaceutical compositions and uses relating thereto |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297367A IL297367A (en) | 2016-08-19 | 2017-08-18 | Ophthalmic pharmaceutical compositions and uses relating thereto |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9867810B1 (https=) |
| EP (2) | EP3500255B1 (https=) |
| JP (3) | JP7297308B2 (https=) |
| KR (2) | KR102472774B1 (https=) |
| CN (2) | CN116726006A (https=) |
| AU (2) | AU2017311636B2 (https=) |
| CA (1) | CA3031370A1 (https=) |
| ES (1) | ES2934790T3 (https=) |
| IL (2) | IL264664B2 (https=) |
| MX (2) | MX2019001877A (https=) |
| PL (1) | PL3500255T3 (https=) |
| PT (1) | PT3500255T (https=) |
| WO (1) | WO2018033792A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1248570A1 (zh) | 2015-05-29 | 2018-10-19 | 西德奈克西斯公司 | D2o稳定化的药物制剂 |
| AU2017311636B2 (en) | 2016-08-19 | 2023-08-10 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
| HUE058931T2 (hu) | 2018-04-24 | 2022-09-28 | Allergan Inc | Pilokarpin hidroklorid alkalmazása presbyopia kezelésére |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| EP3866790A4 (en) | 2018-10-15 | 2022-08-03 | Ocuphire Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES |
| CA3116589A1 (en) * | 2018-10-26 | 2020-04-30 | Ocuphire Pharma, Inc. | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders |
| WO2020226915A1 (en) * | 2019-05-08 | 2020-11-12 | Harrow Ip, Llc | Pharmaceutical compositions for treating presbyopia and methods for fabricating thereof |
| JP7766680B2 (ja) * | 2020-09-11 | 2025-11-10 | イントラタス－ネバダ インコーポレイテッド | 老視、遠視、乱視、低減した立体視、および低下したコントラスト感度を治療するための組成物および方法 |
| MX394625B (es) * | 2020-11-12 | 2025-03-24 | Cesar Alejandro Sanchez Galeana | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia |
| WO2022169959A1 (en) * | 2021-02-04 | 2022-08-11 | Sydnexis, Inc. | Ophthalmic compositions for presbyopia |
| CN115368310B (zh) | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
| WO2023052977A1 (en) * | 2021-09-29 | 2023-04-06 | Avaca Pharma Private Limited | Compositions, methods and uses thereof |
| US20230270671A1 (en) * | 2022-01-14 | 2023-08-31 | Somerset Therapeutics, Llc | Pharmaceutically stable pilocarpine formulations with substantially reduced buffer content and related methods |
| WO2023143575A1 (zh) * | 2022-01-29 | 2023-08-03 | 南京济群医药科技股份有限公司 | 一种m-胆碱受体激动剂化合物及其制备方法和用途 |
| US11969410B2 (en) | 2022-02-09 | 2024-04-30 | Somerset Therapeutics, Llc | Low pH pilocarpine and brimonidine compound formulations and related methods |
| CN117414333A (zh) * | 2023-11-30 | 2024-01-19 | 南京正科医药股份有限公司 | 盐酸毛果芸香碱滴眼液及其制备方法 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4255415A (en) * | 1978-11-22 | 1981-03-10 | Schering Corporation | Polyvinyl alcohol ophthalmic gel |
| IT1229075B (it) | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
| US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| JP2536806B2 (ja) | 1991-03-27 | 1996-09-25 | アルコン ラボラトリーズ インコーポレイテッド | ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物 |
| US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
| US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| SE9401108D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Ophthalmic composition I |
| SE9401109D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
| US6309630B1 (en) * | 1994-05-24 | 2001-10-30 | Insite Vision Incorporated | Non-steroidal anti-inflammatory ophthalmic suspensions |
| US5698533A (en) | 1994-07-26 | 1997-12-16 | Kang; Meng-Che | Ophthalmic pharmaceutical composition |
| US5972326A (en) * | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
| US5612027A (en) | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
| TW389694B (en) * | 1995-08-17 | 2000-05-11 | Novartis Ag | Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics |
| CA2193149C (en) * | 1995-12-22 | 2002-04-23 | David H. Donabedian | Cationic therapuetic agents and delivery systems |
| AU2287597A (en) | 1996-03-13 | 1997-10-01 | Laboratoires Merck Sharp & Dohme - Chibret Snc | Ophthalmological composition of the type which undergoes liquid-gel phase tr ansition |
| EP0995435B1 (en) | 1997-05-14 | 2007-04-25 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension preparations with excellent redispersibility |
| US6265444B1 (en) | 1997-05-23 | 2001-07-24 | Insite Vision Incorporated | Ophthalmic composition |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| SE0002211D0 (sv) | 2000-06-13 | 2000-06-13 | Synphora Ab | Methods and compositions for prevention of myopia |
| WO2002005848A2 (en) | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US6605640B2 (en) | 2001-01-31 | 2003-08-12 | Gerard M. Nolan | Method of treating certain eye diseases |
| US6540990B2 (en) | 2000-09-22 | 2003-04-01 | Gerard M. Nolan | Physiological method of improving vision |
| US6273092B1 (en) | 2000-09-22 | 2001-08-14 | Gerard M. Nolan | Methods for treating various eye disorders |
| US20020160988A1 (en) | 2001-02-20 | 2002-10-31 | Israel Institute For Biological Research | Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof |
| US20040058926A1 (en) | 2001-05-04 | 2004-03-25 | Rebanta Bandyopadhyay | Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| AR034371A1 (es) | 2001-06-08 | 2004-02-18 | Novartis Ag | Composiciones farmaceuticas |
| US20030018382A1 (en) | 2001-07-17 | 2003-01-23 | Pflugfelder Stephen C. | Process for improving vision |
| FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| US20050208102A1 (en) | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| AU2004249137B2 (en) | 2003-06-13 | 2010-03-11 | Alcon, Inc. | Ophthalmic compositions containing a synergistic combination of two polymers |
| CA2534484A1 (en) * | 2003-08-07 | 2005-02-17 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| US20050119262A1 (en) | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
| MXPA03011987A (es) | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
| DE602004022523D1 (de) | 2004-07-02 | 2009-09-24 | Novagali Pharma Sa | Verwendung von Emulsionen zur intra- und periocularen Injection |
| WO2006062875A1 (en) | 2004-12-08 | 2006-06-15 | Merck & Co., Inc. | Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor |
| KR20090053892A (ko) * | 2006-07-25 | 2009-05-28 | 오스모티카 코프. | 점안액 |
| ES2329161T3 (es) | 2006-12-18 | 2009-11-23 | Jorge Luis Benozzi | Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia. |
| EP2094291A1 (en) | 2006-12-21 | 2009-09-02 | Novo Nordisk A/S | Dimeric prolactin receptor ligands |
| KR20090108723A (ko) | 2007-01-31 | 2009-10-16 | 알러간, 인코포레이티드 | 안 약물 송달을 위한 신규한 생체적합물질 및 이의 제조방법 및 용도 |
| WO2008130591A2 (en) | 2007-04-18 | 2008-10-30 | The Gi Company, Inc. | Using trefoil polypeptides to treat eye lesions associated with ophthalmic procedures |
| CN101754748A (zh) | 2007-05-24 | 2010-06-23 | 阿西克斯医疗公司 | 治疗干眼症的制剂和方法 |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| WO2010135731A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8404270B2 (en) | 2009-12-23 | 2013-03-26 | Alimera Sciences, Inc. | Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids |
| MX357635B (es) * | 2011-09-20 | 2018-07-17 | Allergan Inc | Composiciones y metodos para el tratamiento de presbicia, hipermetropia leve, y astigmatismo irregular. |
| US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US10064818B2 (en) * | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| ES2538551B1 (es) * | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
| CN106456584A (zh) * | 2014-02-11 | 2017-02-22 | 阿拉西斯医药公司 | 用于矫正老视的药理学眼科用组合物和其施用 |
| AU2017311636B2 (en) * | 2016-08-19 | 2023-08-10 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
-
2017
- 2017-08-18 AU AU2017311636A patent/AU2017311636B2/en active Active
- 2017-08-18 CA CA3031370A patent/CA3031370A1/en active Pending
- 2017-08-18 ES ES17841144T patent/ES2934790T3/es active Active
- 2017-08-18 CN CN202310735857.7A patent/CN116726006A/zh active Pending
- 2017-08-18 PL PL17841144.3T patent/PL3500255T3/pl unknown
- 2017-08-18 KR KR1020197007252A patent/KR102472774B1/ko active Active
- 2017-08-18 US US15/680,967 patent/US9867810B1/en active Active
- 2017-08-18 WO PCT/IB2017/001140 patent/WO2018033792A2/en not_active Ceased
- 2017-08-18 KR KR1020227041350A patent/KR102588499B1/ko active Active
- 2017-08-18 EP EP17841144.3A patent/EP3500255B1/en active Active
- 2017-08-18 MX MX2019001877A patent/MX2019001877A/es unknown
- 2017-08-18 CN CN201780062092.8A patent/CN109803652A/zh active Pending
- 2017-08-18 IL IL264664A patent/IL264664B2/en unknown
- 2017-08-18 IL IL297367A patent/IL297367A/en unknown
- 2017-08-18 EP EP22209890.7A patent/EP4190328A1/en active Pending
- 2017-08-18 JP JP2019508247A patent/JP7297308B2/ja active Active
- 2017-08-18 PT PT178411443T patent/PT3500255T/pt unknown
- 2017-11-29 US US15/825,505 patent/US20180207136A1/en not_active Abandoned
-
2018
- 2018-07-10 US US16/032,044 patent/US10639297B2/en active Active
-
2019
- 2019-02-15 MX MX2023003124A patent/MX2023003124A/es unknown
-
2020
- 2020-03-26 US US16/831,535 patent/US11129812B2/en active Active
-
2021
- 2021-07-27 US US17/386,138 patent/US11974986B2/en active Active
-
2023
- 2023-06-07 JP JP2023093802A patent/JP7839560B2/ja active Active
- 2023-09-07 AU AU2023226732A patent/AU2023226732A1/en not_active Abandoned
-
2024
- 2024-11-15 US US18/949,157 patent/US20250268867A1/en active Pending
-
2025
- 2025-08-25 JP JP2025139461A patent/JP2025168426A/ja not_active Withdrawn